Abstract
The decision last week by the biotech company Geron to cancel the first-ever clinical trial using human embryonic stem cells and sell off its stem cell programs has shaken the biomedical research community.
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献